Notice Number: NOT-CA-12-016

Key Dates
Release Date: October 10, 2012

Related Announcements
PAR-11-216

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform interested members of the extramural research community about an important change in PAR-11-216, entitled "Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)."  The change is that a Letter of Intent option is now available to applicants submitting applications to PAR-11-216.

The primary objective of PAR-11-216 is to support early phase clinical trials to evaluate the safety and efficacy of imaging agents, imaging and image-guided devices, systems or drug delivery, and quantitative imaging tools.  This funding opportunity supports early phase pilot trials that can be completed within 2 years. Letters of Intent from applicants will help staff members at the NIH and NCI better plan for the reviews of the applications.

Change #1a: Part 1. Overview Information, Key Dates, of PAR-11-216, is amended to add Letter of Intent Due Dates as follows:

30 days prior to the application due date

Change #1b: Part 2, Section IV.2, Content and Form of Application Submission, of PAR-11-216, is amended to add Letter of Intent information as follows:

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to assess responsiveness and to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information (as amended above), prospective applicants are asked to submit a letter of intent that includes the following information:

Descriptive title of proposed research;
Name, address, and telephone number of the PD(s)/PI(s);
Names of other key personnel;
Participating institutions; and
Number and title of this funding opportunity.

The letter of intent should be sent to:
Lori Henderson, Ph.D.
Clinical Trials Branch
Cancer Imaging Program
National Cancer Institute
6130 Executive Boulevard, Room 6062, MSC 7412
Bethesda, MD 20892-7412 (for U.S. Postal Service regular or express mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: 301-451-6449
Email: [email protected]

All other aspects of PAR-11-216 remain unchanged.

Inquiries

Please direct all inquiries to:

Lori A. Henderson, Ph.D.
Clinical Trials Branch
Cancer Imaging Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
6130 Executive Boulevard, Room 6062, MSC 7412
Bethesda, MD 20892-7412 (for U.S. Postal Service regular or express mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: 301-451-6449
Email: [email protected]